The mAb BC8 is specific for CD45 and radiolabeled with 131I was developed as means to myeloablate since the antigen is expressed on the surface of almost all hematopoietic cells, except mature red blood cells and platelets and is also present on AML blasts [174]. Here, PTPRC is linked to acute myeloid leukemia.